Primex Pharmaceuticals AG, a Switzerland-based pharmaceutical company, has named Dan Spacie as its new global commercial head, it was reported yesterday.
Dan Spacie joined Primex Pharmaceuticals from Syneos Health, where he was president, Commercial, Europe. Prior to Syneos, he held several leadership roles including managing director at STADA UK affiliates for five years. He has extensive international leadership experience in growing sales and enhancing profitability of generics, branded pharmaceuticals and launching biopharmaceuticals.
In the new role, Spacie is responsible for global Commercialisation, working with both the company's partners and direct field forces across the portfolio and with the launch of OZALIN in the European Union. He will be part of the executive team headed by CEO Alan Knox and is based in Zug, Switzerland.
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling
Sandoz's Tyruko (natalizumab-sztn) gains FDA approval as first biosimilar for relapsing MS
Nephron Pharmaceutical names new chief procurement officer
Lupin Pharmaceuticals launches Tiotropium Bromide Inhalation Powder, 18mcg/capsule in US